Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force

  title={Screening for Dementia in Primary Care: A Summary of the Evidence for the U.S. Preventive Services Task Force},
  author={Malaz A. Boustani and Britt Ann Peterson and Laura C. Hanson and Russell P. Harris and Kathleen N. Lohr},
  journal={Annals of Internal Medicine},
Dementia is an acquired syndrome of decline in memory and at least one other cognitive domain, such as language, visuospatial, or executive function, that is sufficient to interfere with social or occupational function in an alert person (1). Many diseases can cause the dementia syndrome (hereafter called dementia). Alzheimer disease and cerebrovascular ischemia (vascular dementia) are the two most common causes, and some cases of dementia involve both of these disorders. Although some… 

Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI).

The diagnostic accuracy of the Mini-Mental State Examination (MMSE) at various thresholds for detecting individuals with baseline MCI who would clinically convert to dementia in general, Alzheimer's disease dementia or other forms of dementia at follow-up is determined.

A review approach of Alzheimer Disease and Pharmacological Management

By neurological examination like CT, MRI, and Spinal fluid analysis can occasionally be justified to confirm the dementia syndrome, the treatment are broadly takes place as two types, one is cognitive symptoms treatment, another Non- Cognitive symptoms treatment.

Screening for dementia in community-based memory clinics.

The naming procedure is easy to administer and may have value as a brief initial dementia screen in busy practice settings and more demanding cognitive measures may be needed to improve screening accuracy for MCI.

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting.

The goals of this review were to determine if the Mini-Cog is a cognitive screening test that could be recommended to screen for cognitive impairment in community settings and to identify potential sources of bias.

Initial evaluation of the patient with suspected dementia.

Neuropsychologic testing may be most helpful in situations where screening tests are normal or equivocal, but there remains a high level of concern that the person may be cognitively impaired.

Dementia diagnosis in primary care: Thinking outside the educational box

It is believed that the diagnosis and early clinical management of dementia can be achieved in the setting of primary care, and the pattern of interweaving psychological, social and economic factors relevant to the needs of individual patients and their carers can be met in the community.

Mild cognitive impairment and dementia in primary care: the value of medical history.

Clinical data usually collected on medical history by PCP are useful to detect patients with MCI and dementia and also to predict MCI outcome.

Dementia:A review

The main contributors to dementia (Alzheimer disease; the various dementias: vascular, Lewy body, Parkinson, frontotemporal, and senility; normal pressure hydrocephalus; and Creutzfeldt-Jacobs disease) and other contributors are discussed.

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a primary care setting.

There is insufficient evidence to recommend that the Mini-Cog be used as a screening test for dementia in primary care, and the quality of included studies was found to be low due to a high risk of bias with methodological limitations primarily in their selection of participants.



Detection of Dementia in Primary Care: The Linköping Study

Compared to non-demented patients, the demented had more diagnoses and a higher number of prescribed drugs and Severity and duration of dementia were associated with an increased detection.

Documentation and Evaluation of Cognitive Impairment in Elderly Primary Care Patients

The prevalence of cognitive impairment was determined by screening a group of urban, elderly, primary care patients using the Short Portable Mental Status Questionnaire (SPMQ) and the clinical utility of routine diagnostic investigations are still being debated.

Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention.

  • G. Román
  • Medicine, Psychology
    The Medical clinics of North America
  • 2002

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

These are the first population-based estimates for neuropsychiatric symptoms in MCI, indicating a high prevalence associated with this condition as well.

Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)

Screening different groups of elderly individuals in a general or specialty practice would be beneficial in detecting dementia and persons with memory impairment who were not demented were characterized in the literature as having mild cognitive impairment.

Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study

The data suggest that women are innately more susceptible to AD than men, the lifetime risk among relatives does not support a simple autosomal dominant inheritance pattern of disease, and AD may not be an inevitable concomitant of the aging process, a conclusion that has profound implications for basic and applied AD research.

Early Identification of Alzheimer's Disease and Related Dementias

This Quick Reference Guide for Clinicians contains highlights from Recognition and Initial Assessment of Alzheimer's Disease and Related Dementias, Clinical Practice Guideline No. 19, which was

The detection of dementia in the primary care setting.

Dementia is often unrecognized and undocumented in private practice settings and recognition and documentation rates increased with advancing stage of disease.

Donepezil for mild and moderate Alzheimer's disease.

In selected patients with mild or moderate Alzheimer's disease treated for periods of 12 or 24 weeks, donepezil produced modest improvements in cognitive function and study clinicians rated global clinical state more positively in treated patients, suggesting a small beneficial effect ofdonepezil in improving cognitive function.